Alkermes plc: Alkermes Presents First Clinical Data for Orex

Alkermes plc: Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Alkermes plc: Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

Massachusetts , United States , Ireland , Rio De Janeiro , Estado Do Rio , Brazil , Athlone , Westmeath , Dublin , Waltham , Ohio , Sandy Coombs , Indiens Wirtschaft , Brendon Yee , Craig Hopkinson , Ihre Chancen , Gretchen Murphy , Research Development At Alkermes , Nasdaq , World Sleep Congress , Alkermes , Exchange Commission , Woolcock Institute Of Medical Research , Demonstrated Dose Dependent , Significantly Improved Sleep Latency Compared , Narcolepsy Type , Generally Well Tolerated , All Doses Tested , Pharmacokinetic Profile , Once Daily Dosing , Wake Cycle , Dose Dependent Effects Enable Selection , Planned Phase , Sleep Congress , Sleep Physician , Woolcock Institute , Chief Medical Officer , Executive Vice President , Wakefulness Test , Sustained Attention , Response Task , World Sleep , Private Securities Litigation Reform Act , Annual Report , Selective Orexin Receptor , Der Indien , Die Highlights ,